How to use this page
Type in the search box to filter the medicine cards. You can search a generic name (semaglutide), a drug class (GLP-1), a molecular target (GIP receptor), or a structure word (peptide, small molecule). Results update as you type. Each card has a short mechanism, a target, side effects, patient FAQs, and the limits of the evidence.
Every answer carries an evidence label. The labels mean:
- Regulatory label Comes from the FDA-approved prescribing information (US label) or the EMA product information.
- Phase 3 RCT Comes from a large randomized controlled trial, such as STEP, SURMOUNT, SCALE, CONQUER, EQUIP, COR, or XENDOS.
- Comes from a systematic review that pools many trials.
- Observational data Comes from cohort or registry studies. This shows associations, not proven cause and effect.
- Limited / mixed The evidence is short-term, small, indirect, or conflicting. Treat these statements as uncertain.
Weight-loss numbers from different trials are not directly comparable. Trials use different statistical methods (treatment policy, completers, or multiple imputation), different lengths, and different populations. Compare with care.
Search by molecule
Try a generic name, a class (GLP-1), a target (GIP receptor, MC4R, lipase), a structure word (peptide, small molecule), or a route (weekly injection).
No medicines match that search. Try a shorter word, a generic name, or one of the quick filters above.
Medication cards
Compare medicines
Click a column heading to sort. The table follows your search, so it shows the same medicines as the cards. Weight changes come from the named pivotal trial and are not head-to-head comparisons unless stated.
Bangalore Clinic Dosing & Suitability Protocols
Practical titration steps, BMI criteria, and clinical indications monitored at EQUA Health in HSR Layout, Bangalore.
| Injection (Generic / Common Brand) | Starting Dose & Dose Escalation | Frequency | Average Weight Loss (with lifestyle changes) | Common Side Effects | Suitable BMI Criteria | Suitable Health Conditions | Who Should Avoid / Use With Caution |
|---|---|---|---|---|---|---|---|
| Semaglutide (GLP-1 Receptor Agonist) |
Start: 0.25 mg weekly → gradually increased every 4 weeks → Target: 2.4 mg weekly | Once weekly | ~10–15% body weight loss over 6–12 months | Nausea, vomiting, bloating, constipation, acidity (usually temporary) | BMI ≥30 OR BMI ≥27 with comorbidities | Type 2 diabetes, prediabetes, hypertension, fatty liver, PCOS, dyslipidemia | Pregnancy, breastfeeding, history of medullary thyroid cancer, severe GI disease |
| Semaglutide (Diabetes indication dosing) |
Start: 0.25 mg weekly → 0.5–1 mg weekly | Once weekly | ~5–10% weight loss (secondary benefit) | Similar; nausea more common initially | BMI ≥27 with diabetes | Type 2 diabetes with overweight/obesity | Not approved solely for weight loss; same precautions as weight loss dosing |
| Tirzepatide (Dual GLP-1 / GIP Agonist) |
Start: 2.5 mg weekly → increase every 4 weeks → up to 10–15 mg weekly | Once weekly | ~15–22% body weight loss in many patients | Nausea, diarrhea, constipation, reduced appetite | BMI ≥30 OR BMI ≥27 with metabolic disease | Type 2 diabetes, severe insulin resistance, metabolic syndrome | Pregnancy, severe GI disorders; dose adjustment needed with other diabetes meds |
| Generic Semaglutide (Indian brands – emerging) |
Similar titration to branded formulations (dose depends on manufacturer) | Once weekly | Expected similar to branded semaglutide | Similar GI side effects | Same BMI criteria as branded semaglutide | Same metabolic benefits | Ensure genuine DCGI-approved product; avoid unverified sources |
| Liraglutide (Daily GLP-1 Receptor Agonist) |
Start: 0.6 mg daily → increase weekly → Target: 3.0 mg daily | Daily injection | ~8–12% body weight loss | Nausea, vomiting, injection-site discomfort | BMI ≥30 OR BMI ≥27 with comorbidities | Diabetes, PCOS, fatty liver | Daily injections may reduce compliance; pregnancy contraindicated |
Safety summary
Read this before the FAQs. Red is used only for true warnings.
Boxed warning: GLP-1 and GIP/GLP-1 medicines
Semaglutide, tirzepatide, and liraglutide carry a boxed warning about thyroid C-cell tumors.
- In rodents, these medicines caused thyroid C-cell tumors, including medullary thyroid carcinoma (MTC). It is not known whether they cause these tumors in humans.
- They are contraindicated in people with a personal or family history of MTC, and in people with MEN2 (multiple endocrine neoplasia syndrome type 2).
- Tell your provider about a neck lump, trouble swallowing, or hoarseness that does not go away.
Pancreatitis and gallbladder disease
Acute pancreatitis and gallbladder problems (gallstones, cholecystitis) are reported with GLP-1 and GIP/GLP-1 medicines.
- Get urgent care for severe stomach pain that does not go away, especially if it spreads to your back or comes with vomiting.
- Get urgent care for pain in the upper right belly, fever, or yellowing of the skin or eyes.
- Tell your provider if you have had pancreatitis. The labels advise caution, and these medicines may not be suitable.
Stopping before pregnancy
Semaglutide and tirzepatide should be stopped at least 2 months before a planned pregnancy because they clear slowly from the body. Liraglutide should be stopped when pregnancy is recognized. These medicines are not recommended during pregnancy.
Phentermine/topiramate is contraindicated in pregnancy because of a higher risk of oral clefts. It is available only through a restricted program (REMS) that requires pregnancy testing and counseling.
Other label warnings for incretins
- Kidney injury, usually from dehydration caused by vomiting or diarrhea.
- Worsening of diabetic retinopathy in people with type 2 diabetes.
- Increased resting heart rate.
- Low blood sugar when used with insulin or a sulfonylurea.
- Risk of food or fluid entering the lungs during anesthesia or deep sedation (pulmonary aspiration). Tell your anesthesia team.
- Mood changes and suicidal thoughts are listed in the label; the link is not established. Tell your provider about new or worsening depression.
- Rare reports of sudden vision loss (NAION, non-arteritic anterior ischemic optic neuropathy) with GLP-1 medicines. Seek urgent care for sudden painless vision loss. See the full NAION details in the side effects section of semaglutide, tirzepatide, and liraglutide above, and US FDA Drug Safety Communication (Nov 9, 2026).
Stimulant-type components: phentermine and bupropion
Phentermine (in the phentermine/topiramate combination and as a single medicine) and bupropion (in the naltrexone/bupropion combination) can raise blood pressure and heart rate. Both can disturb sleep and mood.
- Your blood pressure and pulse should be checked before and during treatment. Do not start phentermine if your blood pressure is not controlled.
- Take phentermine in the morning. Late doses commonly cause insomnia.
- Bupropion carries a boxed warning for suicidal thoughts and behaviors. Watch for new or worsening depression, anxiety, or agitation.
- Bupropion lowers the seizure threshold. The risk rises with higher doses, alcohol use, and a history of seizures or eating disorders.
- Do not stop alcohol or a benzodiazepine suddenly while taking naltrexone/bupropion; this can cause seizures.
All medicines are used with diet and activity support
Every pivotal trial gave the medicine together with a reduced-calorie diet, a physical activity goal, and counseling. This is true for STEP 1, SURMOUNT-1, SCALE, XENDOS, CONQUER, EQUIP, and COR-I. The medicine is an add-on, not a replacement for those supports.
Not on this page
This page does not cover supplements, detox products, "natural" weight-loss claims, or diet hacks as treatments for obesity. Those claims are not supported by the evidence standard used here.
Common Patient Questions (30 FAQs)
Detailed answers on injection mechanisms, side effects, PCOS, diabetes reversal, muscle preservation, and consultation protocols by EQUA endocrinologists.
1. What are anti-obesity injectable drugs?
Anti-obesity injectables are prescription medications given under the skin (subcutaneous) that help with significant and sustained weight loss by acting on appetite-regulating hormones in the brain and gut. Most belong to a class called GLP-1 receptor agonists or dual incretin agonists.
2. How do these injections help in weight loss?
They work through multiple scientifically proven mechanisms:
- Reduce appetite by acting on the hypothalamus
- Increase fullness and satiety
- Slow stomach emptying (gastric emptying)
- Reduce calorie intake without increasing hunger
- Improve insulin sensitivity and metabolic health
Weight loss is biological, not just “willpower-based.”
3. Are these injections meant only for cosmetic weight loss?
No. These medicines are medical treatments for obesity, which is a chronic disease, not a cosmetic issue. They are prescribed for:
- BMI ≥30 kg/m², or
- BMI ≥27 kg/m² with conditions like diabetes, hypertension, fatty liver, PCOS, or sleep apnea
4. How much weight loss can one expect?
On average (when combined with lifestyle measures):
- 10–15% body weight loss with GLP-1–based injections
- 15–22% body weight loss with newer dual-acting agents
Results vary based on dose, adherence, genetics, and lifestyle. These results are far superior to diet or exercise alone in many patients.
5. How often are these injections taken?
Most modern anti-obesity injections are:
- Once weekly
- Given using a pre-filled pen
- Injected into the abdomen, thigh, or upper arm
No hospital admission is required.
6. Are these injections safe?
Yes, when properly prescribed and monitored. They have undergone:
- Large randomized controlled trials
- Long-term cardiovascular safety studies
- Real-world post-marketing surveillance
They are approved by international regulatory bodies based on robust safety data.
7. What are the common side effects?
Most side effects are gastrointestinal and temporary, especially during dose escalation:
- Nausea
- Vomiting
- Loose stools or constipation
- Mild acid reflux
These usually reduce over time and are minimized by gradual dose increases.
8. Are there any serious risks?
Serious side effects are rare but include:
- Gallbladder disease (due to rapid weight loss)
- Severe vomiting/dehydration (if misused)
- Pancreatitis (very rare; causal link not definitive)
They are not advised in people with:
- Certain rare thyroid cancers
- Severe gastrointestinal motility disorders
A doctor’s evaluation is essential.
9. Will I regain weight if I stop the injections?
Obesity is a chronic relapsing condition. Stopping treatment may lead to partial weight regain, similar to stopping BP or diabetes medicines. Long-term weight maintenance may require:
- Continued medication
- Or structured transition to lifestyle + maintenance plans
10. Are these injections addictive or habit-forming?
No. They do not act on reward or addiction pathways and do not cause dependency. They work by normalizing appetite signals, not suppressing hunger unnaturally.
11. Can people with diabetes use these injections?
Yes. Many of these drugs were initially developed for type 2 diabetes and:
- Improve blood sugar control
- Reduce insulin resistance
- Lower cardiovascular risk
Dose and choice may vary based on diabetes status.
12. Do these injections reduce belly fat and fatty liver?
Yes. Scientific studies show:
- Significant reduction in visceral (abdominal) fat
- Improvement in fatty liver disease
- Reduction in inflammatory markers
This leads to better metabolic and heart health, not just weight loss.
13. Are diet and exercise still necessary?
Absolutely. These injections are not a replacement, but a biological support tool. Best results occur when combined with:
- Protein-adequate diet
- Strength training
- Sleep optimization
- Stress management
14. How long does one need to be on these medicines?
Treatment duration is individualized. Many patients need long-term therapy, while some may taper after achieving stable weight with lifestyle support. Obesity management is similar to managing diabetes or hypertension.
15. Should these injections be taken without medical supervision?
No. Self-medication or cosmetic misuse can lead to:
- Nutritional deficiencies
- Muscle loss
- Severe side effects
- Improper dosing
They should always be prescribed and monitored by a qualified physician, preferably an endocrinologist.
16. Will these injections cause muscle loss?
Properly used, they do not preferentially cause muscle loss. Any rapid weight loss—by diet, surgery, or medicines—can reduce muscle if:
- Protein intake is inadequate
- Strength training is neglected
With adequate protein and resistance exercise, muscle mass is largely preserved. Doctors monitor body composition, not just weight.
17. Can elderly people use anti-obesity injections?
Yes, with careful supervision. In older adults, benefits often include:
- Improved mobility
- Reduced joint pain
- Better diabetes and BP control
However, dosing is conservative, and emphasis is placed on muscle preservation, nutrition, and hydration.
18. Are these injections safe for people with heart disease?
Yes. Large cardiovascular outcome trials have shown:
- Reduction in heart attacks and strokes
- Lower blood pressure and cholesterol
- Reduced cardiovascular mortality in high-risk individuals
These drugs are now considered cardio-protective, not risky.
19. Do these injections affect hormones or fertility?
They do not damage hormones or fertility. In fact, by improving insulin resistance and weight:
- Men may see improved testosterone levels
- Women with PCOS may regain ovulation regularity
However, they are stopped before planned pregnancy.
20. Can women take these injections during pregnancy or breastfeeding?
No. They are not recommended during:
- Pregnancy
- Breastfeeding
Women of reproductive age should discuss contraception and future pregnancy plans before starting therapy.
21. Will these injections cause nutritional deficiencies?
Not directly. However, because appetite reduces:
- Poor food choices can lead to protein, iron, or vitamin deficiencies
This is why medical nutrition guidance is essential alongside injections.
22. Are these injections the same as crash dieting?
Absolutely not. Crash dieting:
- Triggers starvation responses
- Causes muscle loss and rebound weight gain
Injectable therapies:
- Modify appetite biology
- Reduce hunger signals
- Allow sustainable calorie reduction without starvation
This is medical metabolic correction, not deprivation.
23. Can teenagers or young adults use anti-obesity injections?
In select cases, yes—but only under specialist care. They may be considered when:
- Severe obesity is present
- Complications like diabetes or fatty liver exist
- Lifestyle measures alone have failed
Pediatric or adolescent endocrine supervision is mandatory.
24. Are these injections a replacement for bariatric surgery?
They are not identical, but:
- Many patients can avoid or delay surgery
- Weight loss approaches surgical outcomes in some individuals
- They are reversible and non-invasive
Choice depends on BMI, complications, response to treatment, and patient preference.
25. What is the biggest misconception about anti-obesity injections?
The biggest myth is: “They are shortcuts or cosmetic drugs.”
Scientific truth: They treat the biological drivers of obesity, including:
- Abnormal appetite signaling
- Insulin resistance
- Hormonal dysregulation
They are disease-modifying therapies, not shortcuts.
26. How does PCOS cause weight gain?
PCOS causes weight gain primarily through insulin resistance — up to 75% of women with PCOS have insulin resistance, which locks the body in fat-storage mode. Elevated androgens promote abdominal fat accumulation, while reduced metabolic rate means fewer calories burned at rest. This creates a vicious cycle that requires endocrinologist-led treatment to break.
27. Can thyroid medication alone help me lose weight?
For many patients, thyroid medication alone is not enough for weight loss — especially if insulin resistance, PCOS, or metabolic slowing have developed alongside hypothyroidism. Our endocrinologists combine thyroid optimization with GLP-1 therapy and metabolic support for comprehensive results.
28. What are the early signs of insulin resistance?
Early signs include: weight gain around the abdomen, sugar and carbohydrate cravings after meals, post-meal fatigue, dark skin patches on the neck or armpits (acanthosis nigricans), skin tags, difficulty losing weight despite diet and exercise, and elevated triglycerides on blood work. A fasting insulin test can confirm the diagnosis.
29. Is it safe to take GLP-1 medications if I have diabetes?
Yes. GLP-1 medications were originally developed for type 2 diabetes and are considered the gold standard for weight loss in diabetic patients. They improve blood sugar control, provide cardiovascular protection, and promote 10-22% weight loss. Our endocrinologists carefully adjust diabetes medications during treatment to prevent hypoglycemia.
30. Does EQUA offer online or video consultations?
Yes, EQUA offers video consultations for patients across Bangalore and beyond. Online consultations include the same comprehensive evaluation by our endocrinologists, and medications can be prescribed with proper remote follow-up and monitoring protocols. Contact us to schedule.
Sources
Every quantitative claim on this page is tied to one of these sources. Links go to DailyMed, a DOI, or a PubMed record. If a link breaks, search the full citation.
| ID | Source | Type | Link |
|---|
Regulatory Agencies & Trial Databases
- FDA Drugs@FDA: approved drug products and labeling
- DailyMed (US National Library of Medicine): current prescribing information
- FDA Drug Safety and Availability
- European Medicines Agency: product information
- CDSCO (India): Central Drugs Standard Control Organisation
- PubMed: peer-reviewed clinical trial reports
Evidence-grounded patient education compiled for EQUA Clinic. No commercial sponsorship or third-party drug promotion. Last reviewed: November 2026.
For clinical reviewers
This draft has not been signed off. The open items are listed here so a clinical pharmacist or endocrinologist can close them before public use.
Open items that need clinical review
- Confirm every adverse-event percentage against the current label section 6.1. Setmelanotide reaction rates and the acquired-hypothalamic-obesity safety items need particular care.
- Confirm approval dates, age limits, and indication expansions (for example, tirzepatide for obstructive sleep apnea, semaglutide for cardiovascular risk reduction, and setmelanotide for acquired hypothalamic obesity and ages 2+).
- Confirm whether any newer agents or formulations have been approved since the last review. The page intentionally covers only agents with phase 3 or regulatory support.
- Confirm the missed-dose rules. They differ by product and are easy to mix up.
- Confirm adolescent and pediatric dosing, especially semaglutide 12+, liraglutide 12-17, and setmelanotide age limits.
- Confirm the pregnancy language for each product, including the 2-month stop rule for semaglutide and tirzepatide.
- Confirm the oral-contraceptive interaction text for tirzepatide.
- Confirm the stopping rules at 12 weeks (semaglutide, phentermine/topiramate, naltrexone/bupropion) and 16 weeks (liraglutide).
- Confirm the interpretation of the head-to-head SURMOUNT-5 result and its open-label design.
- Confirm that the page's reading level is 6th-8th grade after final edits, and check the plain-language definitions.
- Confirm the stigma-free language review ("people living with obesity") and remove any residual blaming language.
- Confirm the source links are current and resolve. Recheck quarterly.
- Decide whether phentermine monotherapy belongs on a public page, given its limited long-term evidence.
- Add local/regional labeling notes if the page will be used outside the United States.
- Review the "open questions" text for each drug so it does not overstate or understate uncertainty.
Have questions about your weight loss journey?
Connect with our DM-qualified endocrinologists at EQUA Clinic, HSR Layout, Bengaluru for a personalized medical evaluation.